Studie AIDS / HIV / Sexuell übertragbare Krankheiten

Volume growth was positive (1%) in 2012 after a negative performance in 2011. Demand was due to the contribution of high-income consumers in urban areas, who are responsible for most of the consumption of bleach and whose percentage slightly increased at the end of the review period thanks to the economic improvements in the country. However, volume growth remains low due a lack of consumer demand, as well as manufacturers’ indifferen... mehr

Emergency contraception declines by 4% in current value terms, reaching sales of DKr10.2 million in 2012. 2012’s performance was a continuation of decline from 2011. Unsafe intercourse is a known matter in Denmark as the number of people suffering from sexual diseases and girls having abortions due to unplanned pregnancy is rather high. A decline in sales of emergency contraception products indicates that the authorities’ intentions... mehr

Emergency contraception pills are used in Norway as an emergency situation after unprotected intercourse or contraceptive failure. Emergency contraception can be purchased with or without a prescription, and is intended to prevent unwanted pregnancy. The main aim of the Norwegian health authorities is to make these emergency contraception pills available to all women who need them. Therefore, emergency contraceptives are widely availabl... mehr

Still, there is no emergency contraception available in Azerbaijan. All medicines are Rx only

Euromonitor International's Emergency Contraception in Azerbaijan report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.

mehr

The sales value of emergency contraception continued to grow in 2012, by 7%, as more women turned to these products to avoid unwanted pregnancies. The one-child policy in China, which restricts urban couples to having only one child, has encouraged this trend. Birth control products are commonly used among women to avoid getting pregnant. Though the policy has changed slightly in recent years, allowing second children if one of the pare... mehr

Emergency contraception increased by 3% in current value terms in 2012, reaching €2 million. Consumers are well-aware of the availability of such products without prescription in Finland. Emergency contraception also shows seasonality in Finland, as sales increase in the warmer spring and summer months in particular, peaking after the May Day celebrations and after the Midsummer festival in June. According to the Family Federation, th... mehr

Emergency contraception products in Kazakhstan are Rx, since they might be overused, particularly by younger consumers.

Euromonitor International's Emergency Contraception in Kazakhstan report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market i... mehr

Emergency contraception saw a modest sales growth in 2012. There were not observed any significant shifts in birth rate that could strongly affect the sales of emergency contraception. The sales of emergency contraception traditionally surge in summertime, particularly in June. Short-term peaks in sales are observed also during other holidays such as Easter and Christmas.

Euromonitor International's Emergency Contraception in... mehr

Emergency contraception products continued to rise in popularity in 2012. Hardly ever affected by changes of the economic climate, the category is relying on other factors — such as abundance of products and awareness of them amongst potential customers — to generate sales. From this perspective, the category experienced solid performance.

Euromonitor International's Emergency Contraception in Lithuania report off... mehr

Increased price competition contributed to a slowdown in value growth for Swedish emergency contraception in 2012. This is primarily due to new importers that entered the market and increased competition.

Euromonitor International's Emergency Contraception in Sweden report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to i... mehr

The most significant recent event affecting emergency contraception actually occurred in December 2011, but reverberated throughout 2012. Since 2009, consumers aged 17 years and older were able to purchase emergency contraception without a prescription, albeit behind-the-counter. In February 2011, Teva submitted an application to the FDA requesting non-prescription access to its Plan B emergency contraception drug for those aged under 1... mehr

Emergency contraception is available in Australia. The product is Schedule 3, which means it can only be sold from behind the counter, involving interaction with a pharmacist. The emergency contraceptive pill has been available in Australia since 2004, thus the category is still maturing.

Euromonitor International's Emergency Contraception in Australia report offers a comprehensive guide to the size and shape of the market at... mehr

Its approval delayed several times, the law of Voluntary Interruption of Pregnancy was approved by the Uruguayan Legislative Power and with the necessary regulatory decrees, which began to be applied as of December 1, 2012. Anti-abortion lobbying, the Catholic Church and several members of the opposition however continue to oppose the law and are calling for a referendum to repeal the law. Among those opposing the law is former presiden... mehr

Sales of emergency contraception in Kenya remain virtually negligible, with 169,000 units sold in 2011. Contraception such as condoms is widely promoted. Abortion remains illegal in Kenya.

Euromonitor International's Emergency Contraception in Kenya report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the secto... mehr

In regards to demand for emergency contraception, the demographic situation in Portugal is particularly important. As the birth rate was low over the review period, the government attempted to improve the situation with different methods; nevertheless, it has failed to change the opinion of couples that are concerned about their financial stability. Due to the delicate financial situation, many couples have no choice but to avoid pregna... mehr

OTC emergency contraception began when these products were switched from prescription only to OTC in late 2004. Despite initial more optimistic prospects, sales remained relatively low in the Netherlands, perhaps explained by the relatively low level of unwanted pregnancies among the young population.

Euromonitor International's Emergency Contraception in Netherlands report offers a comprehensive guide to the size and shape o... mehr

The good performance of emergency contraception was influenced by two important factors in 2011. Firstly, the perceptions and attitudes of Austrians towards contraception have changed significantly over the last decade. Nowadays Austrians have more open-minded attitudes towards sexuality in general as well as the rights of women. These positive attitudes had a rather positive impact on sales of emergency contraception products in Austri... mehr

Due to strong religious beliefs in the country and a large rural population, emergency contraception usage has been stymied in Nigeria. However with growing urbanisation and wider retail availability, the category saw quite good growth in current value of 8% in 2011. Educated young adults are starting to view it as an available option, in case of emergency, although at the same time religious views continue to limit its use.

... mehr

Emergency contraception products appeared in Serbia in 2004. At that time, awareness about the presence of these products was insignificant, which was the biggest obstacle to growth. However, in the eight years since, things have visibly changed, as these products are now available in many chemists/pharmacies across the country, whilst awareness of their presence and their usage is now at a significantly higher level. The manufacturer w... mehr

HIV-Associated Lipodystrophy Syndrome — Pipeline Review, H2 2012


Summary


Global Markets Direct’s, 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H2 2012', provides an overview of the HIV-Associated Lipodystrophy Syndrome therapeutic pipeline. This report provides information on the therapeutic development for HIV-Associated Lipodystrophy Syndrome, complete with latest updates, and spe... mehr

In 2011, various figures circulated about the number of terminations per year, in the region of 14,000. As a result there was still room for growth of both Rx and OTC emergency contraception products. OTC emergency contraception products did well until the launch of the Rx ellaOne from Laboratoires HRA Pharma after the authorisation by the European Medicines Evaluation Agency (EMEA) in 2009. This new brand focussed on the niche market o... mehr

Emergency contraception is gaining in popularity among modern women, who are turning to these products to reduce the chances of an unwanted pregnancy in an easy manner. Major cities, including Delhi NCR, Jaipur, Chandigarh, Kanpur and Lucknow are the major sources of demand for emergency contraceptive brands in North India as the population of educated women is greater in these areas, and they are using the product after unprotected int... mehr

Emergency contraception is gaining in popularity among modern women, who are turning to these products to reduce the chances of an unwanted pregnancy in an easy manner. Major cities, including Delhi NCR, Jaipur, Chandigarh, Kanpur and Lucknow are the major sources of demand for emergency contraceptive brands in North India as the population of educated women is greater in these areas, and they are using the product after unprotected int... mehr

In January 2011, Boots Retail Ireland Ltd announced that it would begin supplying emergency contraception without prescription. This was due to a provision found in the amendment to legislation in 2005 relating to emergency contraception, which states that emergency contraception can be offered by 'qualified medical professionals' under protocols set out by a medical professional such as a doctor. Boots stores began offering the morning... mehr

Value sales for emergency contraceptives increased by 1% in current value terms in 2011, a marginal gain over the previous year. Norwegian health authorities concluded the decision to make emergency contraceptives more widely available in mass distribution channels from 1 January 2009 did not impact per capita consumption. There was concern that broad distribution would move the products from an emergency solution to birth control. Norw... mehr

The market entry of parallel importers increased price competition in Swedish emergency contraception in 2011. Increased price competition contributed to a slowdown in value growth.

Euromonitor International's Emergency Contraception in Sweden report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors dri... mehr

The increasingly liberal lifestyles of the youth in Switzerland helped boost value growth in emergency contraception during 2011. Emergency contraception is mainly used by young women, many of whom do not have access to information about preventative birth control methods.

Euromonitor International's Emergency Contraception in Switzerland report offers a comprehensive guide to the size and shape of the market at a national le... mehr

In 2011, sales of emergency contraceptive increased by 10%, to reach £25 million. Bayer Plc’s dominance is being challenged (although not significantly) by Boots private label Emergency Contraceptive Pill, which was launched in October 2010

Euromonitor International's Emergency Contraception in United Kingdom report offers a comprehensive guide to the size and shape of the market at a national level. It provides the l... mehr

Emergency contraception increased by 3% in current value terms in 2011. Growing sales were the result of greater awareness of the availability of emergency contraception. Some of the 2011 increase was also a result of increased VAT on medicines from 8% to 9% in July 2010.

Euromonitor International's Emergency Contraception in Finland report offers a comprehensive guide to the size and shape of the market at a national level. ... mehr

Richter Gedeon Nyrt finally became the only player present in 2011 in emergency contraception in Georgia. There is thus little incentive for Richter Gedeon to push for a stronger share through investment in marketing and new product development. There is also little price competition within emergency contraception, with current value sales remaining steady on an annual basis during the review period. In addition, emergency contraception... mehr

Emergency contraception witnessed sales growth in 2011. The government was not successful in improving the birth rate, which could have affected development of emergency contraception in 2011. The birth rate remained stable and total population was decreasing in Latvia, which explained growth of emergency contraception.

Euromonitor International's Emergency Contraception in Latvia report offers a comprehensive guide to the si... mehr

Emergency contraception grew by 9% in current value terms to reach sales of EUR60,000 in 2011. Escapelle was the only product present at the end of the review period, as it is intended only for exceptional and urgent cases and should not be used as a regular method of contraception. An overall decrease in value growth was evident each year as a result of changing lifestyles of females. In general ... mehr

South Africa remains one of the top countries in Africa where there is serious alcohol consumption amongst teenagers, this trend has led to a general increase in the number of reported cases of unprotected sex amongst young people. Over the past decade ,the government has been working on creating awareness amongst students in colleges and universities in terms of how unwanted pregnancies can be avoided, one way of doing this has been th... mehr

Current value sales of emergency contraception reached a value of EUR7 million in 2011, growing dynamically by 125% in 2011. Although this represents an important growth rate, it is linked to its low base. Nevertheless, the new law on abortion makes that makes it a service financed by the public health system also influenced sales of emergency contraception.

Euromonitor International's Emergency Contraception in Spain report ... mehr

Higher demand for emergency contraception was associated with more liberal sexual behaviour of Thai people. However, greater use of such a product reflects the fact that more consumers were less cautious about their sexual relationships. Even though they seemed to be educated enough to know how to prevent themselves from unwanted pregnancies, they overlooked a better way of initial protection.

Euromonitor International's Eme... mehr

A large number of 28-day pack hormonal contraceptive medicines are available in Belarus. However, most consumers in Belarus still believe that hormonal contraceptives, if used frequently, cause side effects, and should only be used under medical supervision. Most of the hormonal contraceptive medicines in Belarus are Rx products.

Euromonitor International's Emergency Contraception in Belarus report offers a comprehensive guid... mehr

Current value sales of emergency contraception grew by 9% in 2011. This growth was relatively similar to but slightly lower than the CAGR observed during the review period. Even if there are some reimbursed RX emergency contraception medicines available in the marketplace, to get them women need to visit a doctor beforehand this is not necessarily possible in urgent cases of contraception failure or unprotected sex. As a result, French ... mehr

Current value sales of emergency contraception grew by 9% in 2011. This growth was relatively similar to but slightly lower than the CAGR observed during the review period. Even if there are some reimbursed RX emergency contraception medicines available in the marketplace, to get them women need to visit a doctor beforehand this is not necessarily possible in urgent cases of contraception failure or unprotected sex. As a result, French ... mehr

In February 2011, global brand owner Teva Pharmaceutical Industries Ltd filed a petition with the FDA to permit the sale of its Plan B One Step over-the-counter. Since 2006, age restrictions on the sale of emergency contraceptives have required that these products be sold behind the pharmacy counter. Consumers of at least 17 years of age are required to show identification to purchase the products, while those under 17 can only buy them... mehr

Emergency contraception sales grew by 11% in current value terms in 2011. This growth was driven by Escapelle, a product by the Hungarian company Richter Gedeon Ltd, launched in 2007. The launch was supported by an extensive marketing campaign, which included TV, radio, billboard and magazine advertisements and various sponsorships. This not only successfully popularised the product but also created consumer awareness of emergency contr... mehr

Emergency contraception grew by 2% in current terms to reach sales of DKr11 million in 2011. Casual attitudes to sexual intercourse was one of the factors supporting the demand for emergency contraception. These attitudes are perhaps linked to consumers’ lack of concern about the transmission of sexual diseases. Furthermore, a general factor supporting category demand is the growing trend towards self-medication.

Euromonito... mehr

Emergency contraception current value sales increased by 5% with value sales reaching EUR0.5 million in 2011. Emergency contraception posted a very strong performance after the economic crisis ended and consumer purchasing power rose for the first time after eleven consecutive quarters of decline: some women consider these products to be essential. Escapelle 1.5mg and Postinor-2 were the only two products available in 2011.

E... mehr

The decision to switch emergency contraception products from RX to OTC has had only a limited impact on the fortunes of retailers and producers of such products in Lithuania. Although sizeable budgets were assigned for emergency contraception products following the switch in 2009, the global credit crunch and the collapse of the overheated economy prevented the area from achieving its potential. In 2011, spending on product promotion fe... mehr

Emergency contraception current retail value growth of 6% in 2011 was higher than the review period CAGR of 5% due to the fact that the unit price of Levonelle increased from NZ$43.89 per pill in 2010 to NZ$45.91 in 2011. During 2009, the Auckland District Health Board spent NZ$300,000 on a trial and paid pharmacies to make Levonelle available for free for five months ending in March 2009. The free pills were distributed to approximatel... mehr

Having been introduced into the Australian OTC market only in 2004, where it has remained in schedule three, meaning that it can only be sold 'behind the counter” with the involvement of a pharmacist, emergency contraception is a category that is still forming, growing by 7% in current value terms in 2011. This performance was down from the 8% value growth of 2010, suggesting that having experienced strong growth in its early stages, ... mehr

Increased availability and knowledge of emergency contraception products has bolstered recent growth in Canada. Women’s organisations and public health centres have been working to educate women, primarily younger women, of the contraception methods available. This increased awareness has led directly to increased retail sales of emergency contraception products in the country.

Euromonitor International's Emergency Contrace... mehr

Sales of emergency contraception market saw growth of 8% in current value terms in 2011. Owing to public’s concern about the side effects of emergency contraception products, especially the ones with levonorgestrel as active ingredient, the growth rate in this category slowed down slightly over the review period. However, sales value continued to grow in 2011, as demand for emergency contraception remained strong.

Euromonit... mehr

In December 2010, a new brand entered the Israeli market, ending the 10-year monopoly of the Postinor brand marketed by Trima. The new brand, NorLevo, was launched by CTS and stimulated the competitive environment and positive growth in 2011.This launch was among the most significant events during the year in the entire consumer health market, as emergency contraception is a very sensitive type of product, and had been dominated by a si... mehr

Misoprostol, an inhibitor of gastric acid secretion, remained the focus of discussions regarding abortions in Uruguay. This drug is recommended in an official document for use in ending unwanted pregnancy and requires a prescription, although obstetricians/gynaecologists are banned from prescribing it. A patient willing or needing to use this drug must resort either to a gastroenterologist (who will probably refuse to issue a prescripti... mehr

TechNavio’s analysts forecast the Global HIV/AIDS Testing market to grow at a CAGR of 5.2 percent over the period 2010—2014. One of the key factors contributing to this market growth is the steady rise in the number of people prone to HIV/AIDS. The Global HIV/AIDS Testing market has also been witnessing the trend of adoption of AIDS/HIV workplace policies by companies. However, lack of awareness about personal HIV status could p... mehr

TechNavio’s analysts forecast the Global HIV Drugs market to reach US$15.5 billion by 2014. One of the key factors contributing to this market growth is the increase in the use of highly active antiretroviral therapy. The Global HIV Drugs market has also been witnessing the need for novel HIV drugs. However, the expiration of patents of key drugs in 2010 could be a challenge to the growth of this market.

TechNavio’s repo... mehr

Bacteriuria Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Bacteriuria Global Clinical Trials Review, H2, 2011' provides data on the Bacteriuria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bacteriuria. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction ... mehr

Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2011' provides data on the Chronic Kidney Disease (Chronic Renal Failure) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Kidney Dis... mehr

Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2011' provides data on the Focal Segmental Glomerulosclerosis (FSGS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Focal Segmental Glomerulosclerosi... mehr

TechNavio’s analysts forecast the HIV Drugs market in India to reach US$54 million by 2014. One of the key factors contributing to this market growth is the increasing prevalence of HIV in India and the longer life expectancy of HIV patients. The HIV Drugs market in India has also been witnessing the development of immune-based therapies for HIV. However, the inadequate availability of physicians with a specialization in HIV treatment... mehr

Interstitial Cystitis Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Interstitial Cystitis Global Clinical Trials Review, H2, 2011' provides data on the Interstitial Cystitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Interstitial Cystitis. It includes an overview of the trial numbers and their recruitment sta... mehr

Proteinuria - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Proteinuria - Pipeline Review, H2 2011', provides an overview of the Proteinuria therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development... mehr

Urinary Retention Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Urinary Retention Global Clinical Trials Review, H2, 2011' provides data on the Urinary Retention clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Urinary Retention. It includes an overview of the trial numbers and their recruitment status as per the s... mehr

Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global BPH market. The report identifies the key trends shaping... mehr

Whilst there were high expectations for growth since the switch of these products in 2006, sales maintained stable growth. Emergency contraception does not receive high support in terms of advertising or new product development. In addition, OTC products are impacted by competition from prescription-based medicines such as Mifegyne.

Euromonitor International's Emergency Contraception in Netherlands report offers a comprehensi... mehr

Benign Prostatic Hyperplasia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2011', provides an overview of the Benign Prostatic Hyperplasia therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects.... mehr

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2011', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with lates... mehr

According to national statistics the number of single (person) households is growing. In 2009, there were 811,000 single households, whereas in 2010 there were already 829,000 single person households. Both females and males are getting married and starting families later in life (around 26 years of age in females, 30 years of age for males). Regular contraception (hormone pills) for sexual intercourse outside of marriage is increasingl... mehr

The Spanish government decided to allow sales of emergency contraception on an OTC basis in 2009, and the measure was actually implemented in 2010. There are 17 different regions which are responsible for implementing the new law, with Cataluña being the first region actually to see over-the-counter sales of these products. The other regions did not sell such products until 2010, and there are still some pharmacies reluctant to s... mehr

Emergency contraception is a niche market in consumer health. Most people tend to obtain contraceptive pills from public hospitals and therefore do not require to purchase them from pharmacies. Sales occur from people who need to refill their stocks in between visits to the doctor or in emergency cases.

Euromonitor International's Emergency Contraception in Tunisia report offers a comprehensive guide to the size and shape of ... mehr

Emergency contraception suffered from two main factors at the end of the review period. Firstly, the high price of these products deterred many consumers in 2009 and 2010, as the economic downturn eroded many consumers’ disposable income levels. Many consumers were simply unable to afford emergency contraception, particularly as unregulated prices resulted in a wide variance in price across chemists/pharmacies.

Euromonitor ... mehr

Urinary Incontinence - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Urinary Incontinence - Pipeline Review, H2 2011', provides an overview of the Urinary Incontinence therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players inv... mehr

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with l... mehr

Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2011

Summary

GlobalData's clinical trial report, 'Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2011' provides data on the Benign Prostatic Hyperplasia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Benign Prostatic Hyperplasia. It includes an overview of the trial numbe... mehr

Emergency contraception in Belarus remains underdeveloped, with only a few brands being widely recognised. However, the area recorded current retail value growth of 10% in 2010, with sales reaching over BYR2 billion.

Euromonitor International's Emergency Contraception in Belarus report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2006-2010, allo... mehr

Interstitial Cystitis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Interstitial Cystitis - Pipeline Review, H2 2011', provides an overview of the Interstitial Cystitis therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players... mehr

Nocturia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Nocturia - Pipeline Review, H2 2011', provides an overview of the Nocturia therapeutic pipeline. This report provides information on the therapeutic development for Nocturia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nocturi... mehr

Nocturnal Enuresis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Nocturnal Enuresis Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global NE therapeutics market. The report identifies the key trends shaping and driving the global... mehr

In 2010, emergency contraception grew by 8% in current value terms to reach A$1 million.

Euromonitor International's Emergency Contraception in Australia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2006-2010, allowing you to identify the sectors driving growth. Forecasts to 2015 illustrate how the market is set to change.

Prod... mehr

Value share of emergency contraception grew by1% in current value terms to reach DKr11 million in 2010. Consumer demand was affected by the prolonged recession and became stagnant in 2009, when value share grew by 1% after reaching a peak in 2001. The slower sales development in 2010 was partly due to the prolonged negative economic climate, which resulted in less spending on evening events and social entertainment amongst the youth, an... mehr

During 2010, concerns were raised regarding the misuse of emergency contraception products by young women. There were fears that such products were being used as a substitute for birth control products such as condoms and standard contraceptive pills.

Euromonitor International's Emergency Contraception in Israel report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest... mehr

The emergency contraception category grew by 6% in current value terms to reach NGN200 million in 2010. There is continued reduction in the stigma associated with the use of the product as the country becomes more urbanised. Educated young adults are more and more starting to view it as a safer alternative to abortion.

Euromonitor International's Emergency Contraception in Nigeria report offers a comprehensive guide to the si... mehr

Emergency contraception grew by 13% in 2010 to reach R237 million. This was due to the economic slowdown, which limited the amount of income available for disposal and restricted an increase in the sales of emergency contraception. Emergency contraption pills are a relatively expensive over-the-counter product which discourages many consumers.

Euromonitor International's Emergency Contraception in South Africa report offers a... mehr

Casual attitudes to sexual intercourse are supporting the demand for emergency contraception in Sweden. These attitudes are perhaps linked to consumers’ lack of concern for the transmission of sexual infections. In addition to this, a general factor supporting category demand is the growing trend towards self-medication.

Euromonitor International's Emergency Contraception in Sweden report offers a comprehensive guide to the... mehr

Increased liberal attitudes toward sexual relationships among newer generations and rising awareness among women on the necessity of using contraceptive pills in preventing unwanted pregnancies remained the determining factors in boosting sales of emergency contraception in the country. A further 6% growth in 2010, the same as in the previous year, concluded a rosy growth trend for the review period.

Euromonitor International... mehr

Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, Q2, 2011' provides data on the (ARF) (Acute Kidney Injury) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on (ARF) (Acute Kidney Injury). It inc... mehr

Benign Prostatic Hyperplasia Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Benign Prostatic Hyperplasia Global Clinical Trials Review, Q2, 2011' provides data on the Benign Prostatic Hyperplasia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Benign Prostatic Hyperplasia. It includes an overview of the trial numbe... mehr

Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, Q1, 2011' provides data on the Chronic Kidney Disease (Chronic Renal Failure) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Kidney D... mehr

Emergency contraception is still undeveloped in Azerbaijan. The most important factors that hamper the development of this category are low awareness, religion and cultural aspects. However, at the end of the review period, there was an active, educational advertising campaign stressing the fact that it is not a problem to prevent pregnancy after unprotected sexual intercourse.

Euromonitor International's Emergency Contracept... mehr

Emergency contraception increased by 2% in current value terms, reaching sales of €2 million in 2010. Growing sales were the result of better awareness of the availability of emergency contraception. It should be pointed out that emergency contraception was often also purchased to be kept within reach just in case it was needed.

Euromonitor International's Emergency Contraception in Finland report offers a comprehensive gui... mehr

Policies of the Norwegian health authorities seem to contribute to a lower rate of abortions in spite of a trend towards a greater number of sexually active Norwegians and a steadily declining age for sexual debut. The Norwegian Department of Public Health has registered a decrease of 2%, from 18 to 15.9 abortions per 1,000 women, for abortions performed in 2009 compared to the previous year. The number of abortions for teenagers showed... mehr

Inguinal Hernia Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, Q2, 2011' provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of t... mehr

Interstitial Cystitis Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Interstitial Cystitis Global Clinical Trials Review, Q1, 2011' provides data on the Interstitial Cystitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Interstitial Cystitis. It includes an overview of the trial numbers and their recruitment sta... mehr

Overactive Bladder Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Overactive Bladder Global Clinical Trials Review, Q2, 2011' provides data on the Overactive Bladder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Overactive Bladder. It includes an overview of the trial numbers and their recruitment status as per t... mehr

Urinary Incontinence Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Urinary Incontinence Global Clinical Trials Review, Q2, 2011' provides data on the Urinary Incontinence clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Urinary Incontinence. It includes an overview of the trial numbers and their recruitment status ... mehr

The switch of emergency contraception products from Rx to OTC was unexpected by industry players and consumers, especially since Austria is a rather conservative and Catholic country. In addition, it should be noted that the relatively affordable unit price of EUR12 for emergency contraception products in the country is significantly lower than the USD30-40 charged in the US.

Euromonitor International's Emergency Contraceptio... mehr

Emergency contraception sales in Bulgaria reached BGN1 million in 2010. This figure was driven by Escapelle, a product from the Hungarian company Richter Gedeon Ltd, launched in 2006. The launch was supported by a widespread marketing campaign which included TV, radio, billboard and magazine advertisements and sponsorships. This not only made the product popular, but also created consumer awareness of emergency contraception products, t... mehr

Value sales of emergency contraception again registered growth in France, rising by 9% in current value terms. This increase was essentially driven by higher demand, as unit prices were stable. To prevent unplanned pregnancies, in particular after unprotected sex or contraception failure, French women continued to buy the 'morning after pill”. However, in comparison with the previous year, value sales in 2010 increased at a marginally... mehr

The government is keen to encourage a better awareness of birth control methods in Georgia and invested in reproductive health consultants and centres during the review period. As a result of this development, there was a marked rise in the number of legal abortions during the review period. There was also a strong drop in the percentage of births outside of marriage, with this dropping form 50% of overall births in 2005 to just 32% sha... mehr

The 2010 growth rate of 4% was lower than the review period CAGR of 5% as consumers became more aware of the importance of preventative contraceptive methods.

Euromonitor International's Emergency Contraception in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2006-2010, allowing you to identify the sectors driving growth. Forec... mehr

Sales of the emergency contraceptive 'die Pille danach” continued to soar at the end of the review period. Although the growth rate slowed compared with the 23% increase seen in 2009, sales of the morning after pill still grew by an impressive 20% in current value terms in 2010 to CHF5 million.

Euromonitor International's Emergency Contraception in Switzerland report offers a comprehensive guide to the size and shape of the... mehr

Hernia Global Clinical Trials Review, Q2, 2011

Summary

GlobalData's clinical trial report, 'Hernia Global Clinical Trials Review, Q2, 2011' provides data on the Hernia clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial development throughout the world... mehr

Proteinuria - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Proteinuria - Pipeline Review, Q2 2011', provides an overview of the Proteinuria therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development... mehr

Acute Renal Failure (ARF) - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Acute Renal Failure (ARF) - Pipeline Review, Q2 2011', provides an overview of the Acute Renal Failure (ARF) therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF), complete with latest updates, and special features on late-stage and discontinued projects. It also rev... mehr

Over the last couple of years there were no other notable events than the introduction of EllaOne from Laboratoires HRA Pharma. This Rx emergency contraception product entered the Belgian market thanks to authorisation by the European Medicines Evaluation Agency (EMEA). This new brand had to shuffle the cards in the niche of emergency contraception thanks its efficacy until five days after sexual intercourse. Even so, it is an indirect ... mehr

In 2010 the emergency contraception category increased by 8% to reach a total sales value of £22 million. Sales were mainly attributable to the Levonelle brand from Schering Healthcare Ltd, which was the only brand available on the OTC market until October 2010.

Euromonitor International's Emergency Contraception in United Kingdom report offers a comprehensive guide to the size and shape of the market at a national leve... mehr

In 2010 the emergency contraception category increased by 8% to reach a total sales value of £22 million. Sales were mainly attributable to the Levonelle brand from Schering Healthcare Ltd, which was the only brand available on the OTC market until October 2010.

Euromonitor International's Emergency Contraception in United Kingdom report offers a comprehensive guide to the size and shape of the market at a national leve... mehr

Interstitial Cystitis - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Interstitial Cystitis - Pipeline Review, Q2 2011', provides an overview of the Interstitial Cystitis therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players... mehr

Nocturia - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Nocturia - Pipeline Review, Q2 2011', provides an overview of the Nocturia therapeutic pipeline. This report provides information on the therapeutic development for Nocturia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nocturi... mehr

Chemists, doctors and parents raised alarmsregarding the misuse of emergency contraception by young women and teenagers in 2009. With several brands promoting emergency contraceptives with brazen TV ads depicting young couples and girls resorting to the use of the products without serious thought, some young urban adults started using the product repeatedly. Several incidents of serious side effects, including abdominal cramps and menst... mehr

Following the switch from Rx to OTC in April 2009, large sums were assigned to promote the arrival of emergency contraception to consumer health. Magazines and internet sites that targeted young women as the core audience were targeted with advertisements. However, the results were poor. In 2010 sales contracted by -3%, which suggests that the demand for emergency contraception stabilised at 13,000 packages a year.

Euromonito... mehr

Entwöhnugshilfen für Raucher - Singapur

In April 2010, the Ministry of Health (MOH) made changes to the Smoking (Control of Advertisements and Sale of Tobacco) Act in Parliament. The objective of the amendment bill was to strengthen tobacco control. The main changes included more stringent regulations on the import and distribution of tobacco products in Singapore, and amending the definition of tobacco products to ... mehr

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, Q1 2011', provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) therapeutic pipeline. This report provides information on the therapeutic development for Focal Segmental Glomerulosclerosis (FSGS), complete with latest updates, and speci... mehr

Glomerulonephritis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Glomerulonephritis - Pipeline Review, Q1 2011', provides an overview of the Glomerulonephritis therapeutic pipeline. This report provides information on the therapeutic development for Glomerulonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... mehr

Glomerulonephritis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Glomerulonephritis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global glomerulonephritis therapeutics market. The report identifies the key trends shaping and... mehr

Hepatitis B - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Hepatitis B - Pipeline Review, Q1 2011', provides an overview of the Hepatitis B Infection therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis B Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the the... mehr

Hyperoxaluria - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Hyperoxaluria - Pipeline Review, Q1 2011', provides an overview of the Hyperoxaluria therapeutic pipeline. This report provides information on the therapeutic development for Hyperoxaluria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic dev... mehr

Lupus Nephritis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Lupus Nephritis - Pipeline Review, Q1 2011', provides an overview of the Lupus Nephritis therapeutic pipeline. This report provides information on the therapeutic development for Lupus Nephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therape... mehr

During 2010, NRT smoking cessation aids grew 1%, reaching C$135 million in current value terms. Growth was largely bolstered by the declining smoking rate amongst Canadians, rising health awareness, changing societal attitudes towards smoking, and various government initiatives aimed at reducing tobacco consumption. All Canadian provinces now have strict bans on smoking in public places, including foodservice outlets, offices and other ... mehr

Overactive Bladder - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, Q1 2011', provides an overview of the Overactive Bladder therapeutic pipeline. This report provides information on the therapeutic development for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in... mehr

Polycystic Kidney Disease - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Polycystic Kidney Disease - Pipeline Review, Q1 2011', provides an overview of the Polycystic Kidney Disease therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also rev... mehr

Introduction

Although there are a number of novel approaches in early-stage development for HIV, fierce competition is thinning out the late-stage pipeline. Novel treatment approaches, biomedical HIV prevention and genetic profiling could diversify an HIV market currently dominated by a one-pill once-daily regimen.

Features and benefits

* Overview of the HIV late-and early-stage pipeline and potential dr... mehr

Aspergillosis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Aspergillosis - Pipeline Review, Q1 2011', provides an overview of the Aspergillosis therapeutic pipeline. This report provides information on the therapeutic development for Aspergillosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic dev... mehr

Benign Prostatic Hyperplasia - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Benign Prostatic Hyperplasia - Pipeline Review, Q1 2011', provides an overview of the Benign Prostatic Hyperplasia therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects.... mehr

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q1 2011', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with lates... mehr

Introduction

In 2010, Datamonitor estimates that there were about 6.9 million cases of hepatitis C virus in adults aged over 20 in the seven major markets. The majority of these cases (86%) were in those over age 40. Datamonitor also estimates that genotype 1b was the most prevalent genotype with 3.0 million cases, followed by genotype 1a with 1.9 million cases.

Features and benefits

* Gain insight to ma... mehr

Genital Herpes - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Genital Herpes - Pipeline Review, Q1 2011', provides an overview of the Genital Herpes therapeutic pipeline. This report provides information on the therapeutic development for Genital Herpes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Helicobacter Pylori - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Helicobacter Pylori - Pipeline Review, Q1 2011', provides an overview of the Helicobacter Pylori therapeutic pipeline. This report provides information on the therapeutic development for Helicobacter Pylori, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involve... mehr

Hepatitis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Hepatitis - Pipeline Review, Q1 2011', provides an overview of the Hepatitis therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hep... mehr

Hepatitis C - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Hepatitis C - Pipeline Review, Q1 2011', provides an overview of the Hepatitis C therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development... mehr

Herpes Simplex - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Herpes Simplex - Pipeline Review, Q1 2011', provides an overview of the Herpes Simplex therapeutic pipeline. This report provides information on the therapeutic development for Herpes Simplex, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic... mehr

Herpes Zoster - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Herpes Zoster - Pipeline Review, Q1 2011', provides an overview of the Herpes Zoster therapeutic pipeline. This report provides information on the therapeutic development for Herpes Zoster, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic dev... mehr

HIV / AIDS - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'HIV / AIDS - Pipeline Review, Q1 2011', provides an overview of the HIV / AIDS therapeutic pipeline. This report provides information on the therapeutic development for HIV / AIDS, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for... mehr

HIV-1 Infection - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'HIV-1 Infection - Pipeline Review, Q1 2011', provides an overview of the HIV-1 Infection therapeutic pipeline. This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therape... mehr

Influenza - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Influenza - Pipeline Review, Q1 2011', provides an overview of the Influenza therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inf... mehr

Influenza A - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Influenza A - Pipeline Review, Q1 2011', provides an overview of the Influenza A Infection therapeutic pipeline. This report provides information on the therapeutic development for Influenza A Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the the... mehr

Meningitis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Meningitis - Pipeline Review, Q1 2011', provides an overview of the Meningitis therapeutic pipeline. This report provides information on the therapeutic development for Meningitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for... mehr

Mycobacterium Avium-Intracellulare - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Mycobacterium Avium-Intracellulare - Pipeline Review, Q1 2011', provides an overview of the Mycobacterium Avium-Intracellulare therapeutic pipeline. This report provides information on the therapeutic development for Mycobacterium Avium-Intracellulare, complete with latest updates, and special features on late-stage an... mehr

NRT smoking cessation aids saw decline of 8% as sales accounted for a value of EEK5 million in 2010. Although the number of smokers in Estonia is decreasing, NRT smoking cessation aids sales have not increased. As consumers in Estonia were trying to save, smoking habits were often abandoned without the help of NRT smoking cessation aids. In other cases, people were not quitting smoking at all as they considered these products to be too ... mehr

NRT smoking cessation aids appeared in 2006 in Latvia. Demand for the products was due to consumers deciding to stop smoking. The market was not yet established in 2010 and was small, with less than 1% of total consumer health.

Euromonitor International's NRT Smoking Cessation Aids in Latvia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2... mehr

Russian authorities have become increasingly concerned with the problem of smoking. In 2010 regulations on the subject were reviewed twice. New initiatives proposed a ban on tobacco smoking in public places, a tightening of packaging requirements for tobacco manufacturers, and requirements for retailers to sell tobacco products only in shops with areas exceeding 50 sq m. A gradual annual increase of tobacco taxes was proposed to reach E... mehr

In April 2010, GlaxoSmithKline brought significant innovation to the NRT smoking cessation aids category with the launch of its Nicorette Mini Lozenge. This product is significantly smaller and dissolves three times faster than traditional lozenges currently on the market. In addition, these 'mini lozenges” are sold in three small vials containing 27 lozenges each, a packaging format that both maximises portability and ensures discree... mehr

Tuberculosis - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Tuberculosis - Pipeline Review, Q1 2011', provides an overview of the Tuberculosis therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic develop... mehr

Urinary Incontinence - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Urinary Incontinence - Pipeline Review, Q1 2011', provides an overview of the Urinary Incontinence therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players inv... mehr

Urinary Tract Infections - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Urinary Tract Infections - Pipeline Review, Q1 2011', provides an overview of the Urinary Tract Infections therapeutic pipeline. This report provides information on the therapeutic development for Urinary Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews... mehr

Aids Associated Dementia - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Aids Associated Dementia - Pipeline Review, Q1 2011', provides an overview of the Aids Associated Dementia therapeutic pipeline. This report provides information on the therapeutic development for Aids Associated Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews... mehr

Over the last three decades, HIV/AIDS has remained the major health priority for many countries across the globe. Although this sector has seen a significant number of developments in recent years, AIDS-related illnesses remain one of the leading causes of death globally and is projected to continue as a significant global cause of premature mortality in the coming decades (World Health Organization, 2008). In 2008 Sub-Saharan Africa an... mehr

Introduction

Sexually transmitted diseases (STDs) represent a significant health threat given their potentially serious complications and association with increased transmission of human immunodeficiency virus (HIV). High disease burdens, low diagnosis and treatment rates, and a lack of marketed interventions for the prevention of most STDs highlight the clinical and commercial potential in this area.

Scope
mehr

Introduction

In 2009, HIV antiretroviral sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10.8% between 2005 and 2009. While new cross-class fixed dose combinations will ensure market growth until 2015, Datamonitor expects major patent expiries and rising pressure to reduce healthcare costs to trigger a decline in HIV sales in the second half of the forecast period until 2019.

Reaso... mehr

Introduction

In 2009, HIV antiretroviral sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10.8% between 2005 and 2009. While new cross-class fixed dose combinations will ensure market growth until 2015, Datamonitor expects major patent expiries and rising pressure to reduce healthcare costs to trigger a decline in HIV sales in the second half of the forecast period until 2019.

Scope... mehr

HIV-AIDS — Pipeline Assessment and Market Forecasts to 2016

Summary

GlobalData’s report, 'HIV/AIDS — Pipeline Assessment and Market Forecasts to 2016” provides an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insights on the prevalent competitive landscape and t... mehr

Introduction

Faced with limited growth opportunities in western markets, HIV drug developers are looking to expand into emerging markets, marked by a higher disease burden and greater medical unmet need. Efforts to improve treatment coverage coupled with a growing affluent middle class and private sector have turned countries like Brazil, Russia or India into a promising commercial opportunity.

Scope

*An... mehr

Life Science Analytics', AIDS_HIV Therapy Area Pipeline Report contains detailed information on the aids_hiv drug pipeline. This report provides insight into the pipeline status of aids_hiv drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pip... mehr

Introduction

China, Taiwan, South Korea and Turkey represent highly endemic areas for viral Hepatitis. For this report, 180 high-prescribing physicians where surveyed in these countries, providing a breakdown of numbers of treated patients and the most frequently prescribed regimens.

Scope

*Current epidemiology of HBV and HCV, including prevalence, diagnosis and treatment rates as well as patient split b... mehr

The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Summary

GBI Research, the leading business intelligence provider, has released its latest research “The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.” The report provides in-depth analysis of unmet needs, drivers ... mehr

Introduction

In 2008, antiretroviral sales across the seven major markets totaled $10.7 billion, growing at a CAGR of 12.8% between 2005 and 2008. Datamonitor expects this expansion to slow down. Despite drivers such as new product launches, earlier treatment initiation, decreasing mortality and an increase in HIV prevalence, a series of patent expiries will impact branded sales from 2011.

Reasons to Purchase
... mehr

HIV is a lentivirus and attacks immune system which leads to death. The continuous research has developed treatment for HIV which has made a separate market for HIV drugs. The HIV drug market is increasing due to increasing awareness and diagnosis rates. There are around five million people in low and middle income countries who do not have access to AIDS drugs. HIV is very common in Southern African region. Botswana and Zimbabwe are t... mehr

Life Science Analytics', 'Infections AIDS HIV ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by compa... mehr